Handelsavisen
prelaunch
Companies Financials NIVA.NS
NI
NIVA.NS NSE (India) Life & Health Insurance

Niva Bupa Health Insurance Company Ltd

$84,08
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
5,7 %
Net margin
Debt / equity
0,07
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Niva Bupa Health Insurance Company Ltd provides health and life insurance products in India, generating revenue primarily through premium income and investment returns on its insurance reserves.

Business. Niva Bupa Health Insurance Company Ltd (NIVA.NS) is an Indian life and health insurance provider that generates revenue primarily through premium income. The company is headquartered in India and is listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorFinancials
Business sectorInsurance
IndustryLife & Health Insurance
Generated · model-assisted
Sell-side consensus
BUY9 analysts
7 buy2 hold0 sell
Avg 12m price target86,67

Analyst recommendations

9 analysts · consensus Buy
Buy7
Hold2
Sell0
12-month price target
86,67
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
9 analysts · indicative
Ownership
not yet wired
Profitability
5,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NIVA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials · THIS SECTOR−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NIVA.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Niva Bupa Health Insurance Company Ltd (NIVA.NS) is an Indian life and health insurance provider that generates revenue primarily through premium income. The company is headquartered in India and is listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorFinancials
    Business sectorInsurance
    IndustryLife & Health Insurance
    AI synthesis
    GENERATED

    Niva Bupa maintains a conservative capital structure with a debt-to-equity ratio of 0.07, indicating minimal leverage and strong equity backing. The company's liquidity position is assessed as medium, with free cash flow of INR 1.97 billion and operating cash flow of INR 16.54 billion, but net cash is negative after subtracting total debt. This suggests that while the company generates robust cash from operations, it is currently using cash to service or reduce debt obligations.

    Profitability metrics show a return on equity (ROE) of 5.65% and a return on assets (ROA) of 2.04%. These figures are below the industry median for ROE and ROA in the Life & Health Insurance sector, indicating that Niva Bupa is underperforming relative to its peers in terms of capital efficiency and asset utilization.

    The company's revenue is concentrated in its core health and life insurance segments, with no material geographic diversification beyond India. This concentration exposes the company to regulatory and macroeconomic risks specific to the Indian market, particularly in the insurance sector, which is subject to evolving policy frameworks and consumer behavior shifts.

    Looking ahead, Niva Bupa is projected to experience moderate growth in the current fiscal year, with revenue and operating income expected to increase by low single-digit percentages. The company's capital expenditure has been negative in recent periods, suggesting a focus on cost optimization rather than expansion. Analysts have assigned a mean recommendation of 1.89, indicating a generally positive outlook, with 3 strong-buy and 4 buy ratings.

    Risk factors include the company's reliance on a single market and the potential for regulatory changes affecting premium pricing and claims management. The risk of dilution is assessed as low, with no significant share issuance activity in the recent financial period. However, the negative net cash position after debt suggests that the company may need to access external financing in the near term, which could introduce new risks.

    Recent filings and transcripts indicate that Niva Bupa is focused on expanding its digital offerings and improving customer retention in a competitive market. The company has also emphasized its investment strategy, which is aligned with maintaining a strong balance sheet and generating stable returns for shareholders.

    Key takeaways
    • Niva Bupa has a conservative capital structure with a low debt-to-equity ratio of 0.07.
    • The company's ROE of 5.65% and ROA of 2.04% are below the industry median, indicating underperformance in capital efficiency.
    • Revenue is concentrated in India, exposing the company to regulatory and macroeconomic risks.
    • Analysts project moderate growth with a mean recommendation of 1.89, suggesting a generally positive outlook.
    • The company's liquidity position is medium, with a negative net cash position after subtracting total debt.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $84,08
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $37.76B
    Net cash
    -$2.50B
    Current ratio
    Debt / equity
    0.1
    ROA
    2.0%
    ROE
    5.7%
    Cash conversion
    775.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,72
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    9
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,72
    Revenueno estimateno estimate63,8B INR
    Operating incomeno estimateno estimate-1,0B INR
    Full-year consensus mean (period as reported by source) · consensus in INR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution9 analysts
    Strong buy3
    Buy4
    Hold2
    Sell0
    Strong sell0
    12-month price target$86,67 · Median $85,00
    Low $78,00High $95,00
    Operating income · consensus-1,0B INR
    EPS surprise
    +66,7 %
    reported vs consensus · beat
    Revenue surprise
    −15,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$78,00
    Mean$86,67
    Median$85,00
    High$95,00
    Spot$84,08
    +3.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE5,7 %Below median
    D/E0,07Above median
    Cash Conv7,75Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Niva Bupa Health Insurance Company Ltd Market data — financials · 2026-05-28
    • Niva Bupa Health Insurance Company Ltd Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NIVA.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage